Related Experiment Video
Updated: Jul 6, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
N A Cross1, E A Waterman, N Jokonya
1Academic Urology Unit, University of Sheffield Medical School, Sheffield, UK. n.a.cross@shef.ac.uk
Abstract:
Factors that regulate the induction of apoptosis of tumour cells are potential candidates for therapeutic intervention for the majority of cancers. Studying modifiers of apoptotic responses, such as members of the tumour necrosis factor receptor superfamily, may give clues as to how induction of apoptosis in tumours could be maximized to enhance the benefit of treatment regimes. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anti-tumour molecule since its activity is specific for tumour cell populations. TRAIL binds to death receptors, inducing apoptosis in susceptible cells. The mechanisms which determine whether tumour cells are susceptible to TRAIL are unclear, and several mechanisms have been proposed, including expression of osteoprotegerin (OPG), decoy receptors, and factors that affect intracellular signalling of pro-apoptotic molecules, such as c-FLIP. Here we show that experiments to modulate the activity of one of these factors, OPG, by over-expression and also by stable knockdown of OPG expression, alters the TRAIL sensitivity of PC3 prostate cancer cells. However we show that some observed effects, which appear to support the hypothesis that OPG prevents TRAIL-induced apoptosis of tumour cells, may be due to variation of the TRAIL response of sub-clones of tumour cells, even within a cloned population. These results highlight potential limitations of experiments designed to test contribution of factors affecting intrinsic apoptosis susceptibility using cloned tumour cell populations.
Insights
Osteoprotegerin (OPG) modulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity in prostate cancer cells. However, observed effects may stem from cellular sub-clone variations, not solely OPG activity.
Area of Science:
- Cancer biology
- Molecular oncology
- Cell death pathways
Background:
- Apoptosis induction in tumor cells is a key therapeutic strategy for cancer.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise as an anti-cancer agent due to its tumor-specific activity.
- Mechanisms determining tumor cell susceptibility to TRAIL-induced apoptosis, including osteoprotegerin (OPG) and c-FLIP, are not fully understood.
Purpose of the Study:
- To investigate the role of osteoprotegerin (OPG) in regulating TRAIL-induced apoptosis in PC3 prostate cancer cells.
- To determine if modulating OPG expression affects tumor cell sensitivity to TRAIL.
- To assess potential confounding factors, such as cellular heterogeneity, in TRAIL sensitivity studies.
Main Methods:
- Over-expression of OPG in PC3 prostate cancer cells.
- Stable knockdown of OPG expression in PC3 prostate cancer cells.
- Assessment of TRAIL sensitivity in PC3 cells with altered OPG levels.
Main Results:
- Modulating OPG activity, through over-expression or knockdown, altered the TRAIL sensitivity of PC3 prostate cancer cells.
- Observed alterations in TRAIL sensitivity were potentially influenced by variations in TRAIL response among sub-clones within the cell population.
- These findings suggest that cellular heterogeneity can impact experimental outcomes when studying factors affecting intrinsic apoptosis susceptibility.
Conclusions:
- OPG's role in TRAIL-induced apoptosis is complex and may be masked by clonal variation within tumor cell populations.
- Experimental designs investigating apoptosis modifiers should account for potential heterogeneity in tumor cell responses.
- Further research is needed to elucidate the precise mechanisms of TRAIL resistance and susceptibility in cancer therapy.
